Lin Ding

Lin Ding

Auto-generated profile, based on publicly available information

Lin Ding

1] National Center for Drug Screening & State Key Laboratory of Natural Medicines, China Pharmaceutical University, Jiangsu Province, 210009, P. R. China [2]

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Cytokine
Verified
Journal Article
Closed access
WHWaseem Hassan
Waseem Hassan
LDLin Ding
Lin Ding
RGRongyin Gao
Rongyin Gao
JLJun Liu
Jun Liu
JSJing Shang
Jing Shang

1 January 2013 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
YLYu Li
Yu Li
LDLin Ding
Lin Ding
WHWaseem Hassan
Waseem Hassan
DADaoud Abdelkader
Daoud Abdelkader
JSJing Shang
Jing Shang
Obesity is a major risk factor for insulin resistance and type 2 diabetes. Adipose tissue is now considered to be an active endocrine organ that secretes various adipokines such as adiponectin, leptin, resistin, tumour necrosis factor-α, and interleukin-6. Recent studies have shown that these factors might provide a molecular link between increased adiposity and impaired insulin sensitivity. Since hepatic insulin resistance plays the key role in the whole body insulin resistance, clarification of the regulatory processes about hepatic insulin resistance by adipokines in rodents and human would seem essential in order to understand the mechanism of type 2 diabetes and for developing novel therapeutic strategies to treat it.

6 May 2014 in Scientific Reports
Verified
Journal Article
Open access
LDLin Ding
Lin Ding
JLJun-Lin Liu
Jun-Lin Liu
WHWaseem Hassan
Waseem Hassan
LWLulu Wang
Lulu Wang
FYFangrong Yan
Fangrong Yan
JSJing Shang
Jing Shang
To investigate a possible methodology of exploiting herbal medicine and design polytherapy for the treatment of non-alcoholic fatty liver disease (NAFLD), we have made use of Cichorium glandulosum Boiss et Huet (CG), a traditional Chinese herbal medicine that has been proven to be effective in treating hepatic diseases. Here, we report that the extract of CG effectively reduced lipid accumulation under conditions of lipid overloading in vivo and in vitro (in a rat high-fat diet model and a hepG2 cell model of free fatty acid treatment). CG extract also protected hepatocytes from injury and inflammation to aid its lipid-lowering properties (in a rat high-fat diet model and a L02 cell model of acetaminophen treatment). Serum chemistry analysis accompanied by in vitro drug screening confirmed that CG-4, CG-10 and CG-14 are the lipo-effective components of CG. Western blotting analysis revealed that these components can regulate key lipid targets at the molecular level, including CD36, FATP5 and PPAR-[agr], thus the lipid oxidation and lipid absorption pathways. Finally, we adopted the experimental design and statistical method to calculate the best combination proportion (CG-4: CG-10: CG-14 = 2.065: 1.782: 2.153) to optimize its therapeutic effect.